ISPE Appoints New Leaders for the Upcoming Term
The International Society for Pharmaceutical Engineering (ISPE) has officially announced the results of its 2025-2026 Board of Directors election. Those selected will take on their roles at the annual meeting and expo of ISPE, a pivotal event for the pharmaceutical community.
Key Company Leadership Changes
As the new Directors step up, they will play a vital role in shaping the strategic direction of ISPE, which focuses on enhancing the pharmaceutical industry. The upcoming annual meeting is set to be a platform where these new leaders can share their vision.
Executive Committee Members
Leading the board is Vivianne Arencibia, who is currently the Vice President for Global Quality Systems and Compliance at Moderna. Along with her, Ylva Ek, the Founder of Robur Life Science Advisory AB, has been appointed as Vice Chair. The Treasurer position has been filled by David Churchward from AstraZeneca, while Georg Singewald from Roche/Genentech takes the role of Secretary.
Returning and New Board Members
Returning for a second term is Liz Dooley from Johnson & Johnson. New appointments also include Jose Caraballo from Kite, Victor Cruz from Eli Lilly, and Francesco Intoccia from CSL Behring. These individuals bring with them extensive experience and knowledge from their respective fields.
Continuing Contributions
Several Directors elected in the previous cycle will continue serving the ISPE Board through the 2025-2026 period. This includes industry veterans like Norman Goldschmidt from Genesis AEC and James Grunwald from Arcadis, who will ensure continuity in leadership.
Recognizing Departing Board Members
With new appointments come the departures of some board members. Scott Billman, Sarah Pope Miksinski, and Timothy Watson from Gilead Sciences, among others, have completed their service and will be thanked for their contributions.
Election Process Overview
The recent election was conducted seamlessly by an impartial third party to ensure integrity in the results, giving confidence to both the members of ISPE and the broader pharmaceutical community.
About ISPE
The International Society for Pharmaceutical Engineering is a nonprofit organization dedicated to advancing the pharmaceutical industry through scientific and regulatory development. With a global membership exceeding 23,000 individuals, ISPE plays a crucial role in tackling complex challenges within the industry across over 120 countries. The organization champions innovation while supporting workforce development and technical collaboration.
Frequently Asked Questions
What is the main role of the ISPE Board of Directors?
The ISPE Board of Directors guides the governance and strategic direction of the organization, ensuring it meets the needs of its global membership.
When will the newly elected Directors assume their positions?
The newly elected Directors will start their roles during the annual meeting and expo, thereby setting plans for the next term.
Who are some notable members of the new ISPE Executive Committee?
New members include Vivianne Arencibia from Moderna and Ylva Ek from Robur Life Science Advisory AB, reflecting strong leadership in the pharmaceutical sector.
How does ISPE support the pharmaceutical industry?
ISPE supports the industry through collaboration on technical, regulatory, and compliance issues, alongside member development in an evolving marketplace.
What is the significance of the annual ISPE Meeting and Expo?
The annual meeting and expo serve as a pivotal event for industry professionals to exchange knowledge, learn about innovative practices, and network across the pharmaceutical field.
